MENU

News

Latest News Articles

05.17.19

Phase 2 Results for Evobrutinib Suggests Efficacy and Safety for Treatment of Multiple Sclerosis

In a double-blind phase 2 study (NCT02975349), adult participants with multiple sclerosis (MS) treated with evobrutinib (75 mg taken orally once or twice daily)...

05.17.19

Diroximel Fumarate for Multiple Sclerosis Shows Promise of Efficacy With Fewer Gastrointestinal Side Effects

Diroximel fumarate (DRF)(ALKS8700, BIIB098; Alkermes, Waltham, MA and Biogen, Cambridge, MA) is an oral fumarate in development for treatment of multiple...

05.14.19

Levodopa-Carbidopa Infusions for Treatment of Motor Fluctuations in Parkinson’s Disease

A prodrug formulation of levodopa-carbidopa delivered as an intestinal gel (LCIG) (Duopa; Abbvie, Chicago, IL) is approved by the Food and Drug Administration...

05.13.19

Zolgensma—Gene Replacement Therapy—for Treatment of Spinal Muscular Atrophy

Results from multiple trials of SMN1gene-replacement therapy (Zolgensma; Avexis, Bannockburn, IL) show promise for single-dose treatment of spinal muscular...

05.13.19

Combination of Elenbecestat and BAN2401 to Be Tested for Alzheimer’s Prevention

The Alzheimer’s Clinical Trials Consortium (ACTC) has announced 2 studies of combination therapy of elenbecestat (Eisai, Woodcliff Lake, NJ) and...

05.10.19

Nusinersen for Treatment of Spinal Muscular Atrophy in Presymptomatic Children, Pivotal Trial Participants, and Adults

Over 7,500 individuals have been or are being treated with nusinersen (Spinraza; Biogen, Cambridge, MA). Across clinical trials and the real-world setting,...

05.10.19

Precision Olfactory Drug Delivery to Upper Nasal Cavity With Improved Bioavailablity in Development for Headache, Parkinson’s, and More

Impel Neuropharma (Seattle, WA) is developing new therapeutic formulations for delivery of therapeutic compounds to the upper nasal cavity with their precision...

05.10.19

Global Kinetics Wearable Device Provides Clinically Meaningful Improvement in Assessing and Managing Parkinson’s Disease

Using a wearable technology (PKG) (Personal Kinetograph; Global Kinetics, Portsmouth, NH) cleared by the Food and Drug Administration (FDA), over 40,000 reports...

05.10.19

Lasmiditan for Acute Migraine Treatment Effective in People with Migraine Nonresponsive to Triptans

Post hoc analysis shows that participants who took 100 mg or 200 mg of lasmitidan had statistically significant increases in the rate of pain relief and freedom...

05.08.19

Phase 3 Results for Inebilizumab Show Reduced Risk of Neuromyelitis Optica Spectrum Disorder Relapse

Treatment with inebilizumab (VielaBio, Gaithersburg, MD) reduced relapses of neuromyelitis optica spectrum disorder (NMOSD) by 77% after 28 weeks of...

05.08.19

FDA Approves First Treatment for Children with Lambert-Eaton Myasthenic Syndrome

The Food and Drug Administration (FDA) has approved amifampridine (Ruzurgi; Jacobus Pharmaceutical Company, Princeton, NJ) for treating Lambert-Eaton myasthenic...

05.07.19

Ubrogepant, an Oral CGRP-Receptor Antagonist, Provides Relief for Migraine Nonresponsive to Triptans

Treatment with ubrogepant (Allergan, Madison, NJ) resulted in similar magnitudes of pain relief for participants who had triptan-nonreponsive migraine (n...

05.07.19

Phase 2 Results for Atogepant-An Oral CGRP Receptor Antagonist-for Episodic Migraine Prevention

In a phase 2b/3 clinical trial (NCT02848326), adults treated with atogepant (Allergan, Madison, NJ) had greater reduction from baseline in monthly migraine days...

05.06.19

For Patients, A New Guideline on Tic Disorders and Tics in Tourette Syndrome Released

Tics are unvoluntary and repetitive and can be motor (twitches, movements) or vocal (a sound—sniffing, hooting, or speaking words out of context). The...

05.06.19

First Evidence-Based Guideline for Neurologists Diagnosing and Treating Tic Disorders and Tics in Tourette Syndrome Released

The American Academy of Neurology has released new guidelines for tic disorders and tics in Tourette’s syndrome. The guideline is endorsed by the Child...

05.06.19

FDA Clears Targeting Software for Parkinson’s Disease Deep Brain Stimulation

The Food and Drug Administration (FDA) has granted marketing clearance for a software package (Surgical Information Sciences, Plymouth, MN) to guide...

05.05.19

Combination Therapy With Memantine and Cholinesterase Inhibitors for Alzheimer’s Disease

Data analysis shows that combination treatment with memantine (MEM) (Namenda; Allergan, Madison, NJ) and cholinesterase inhibitors (ChEI) is more effective for...

05.05.19

Phase 3 Results Show Eculizmab Reduces Neuromyelitis Optica Relapses

In a phase 3 clinical trial (NCT01892345) treatment with eculizumab (Soliris; Alexion, New Haven, CT) significantly reduced relapse rates for persons with...

05.05.19

Opicapone Increases ON Time for Parkinson's Disease

In 2 phase 3 studies, treatment with opicapone (Neurocrine Biosciences, San Diego, CA) increased ON time without troublesome dyskinesia almost twice as much as...

05.05.19

Valbenazine Improvements for Tardive Dyskinesia Are Sustained in People Taking Different Neuropsychiatric Drugs

Pooled data analysis from 2 phase 3 trials shows that valbenazine (Ingrezza; Neurocrine Biosciences, San Diego, CA), approved for treatment of tardive...

Show More
This Month's Issue
Stroke Spotlight: Subarachnoid Hemorrhage and Cerebral Vasospasm

Saif A. Bushnaq, MD; and Sunil A. Sheth, MD

Migraine Preventive Therapies

Charisse Litchman, MD, FAHS; and Sirisha Sanamandra, MBBS